世界の循環腫瘍細胞(CTC)予後技術市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20DC10841)
◆英語タイトル:Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20DC10841
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年12月
◆ページ数:103
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥462,840見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥694,260見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥925,680見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、循環腫瘍細胞(CTC)予後技術の世界市場を広く調査・分析し、今後の市場展望をまとめております。循環腫瘍細胞(CTC)予後技術の種類別市場規模(腫瘍細胞濃縮、腫瘍細胞検出)、用途別市場規模(前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):AdnaGen、Vitatex、Epic Sciences、ACDBio、Silicon Biosystems、Celula、Rarecells、Fluxion Biosciences、
・地域別グローバル市場分析 2015年-2020年
・循環腫瘍細胞(CTC)予後技術の北米市場(アメリカ、カナダ、メキシコ)
・循環腫瘍細胞(CTC)予後技術のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・循環腫瘍細胞(CTC)予後技術のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・循環腫瘍細胞(CTC)予後技術の南米市場(ブラジル、アルゼンチン)
・循環腫瘍細胞(CTC)予後技術の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:腫瘍細胞濃縮、腫瘍細胞検出
・用途別分析:前立腺がん、乳がん、結腸直腸がん、肺がん、卵巣がん、膵臓がん
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 14.3% in the forecast period of 2020 to 2025 and will expected to reach USD 2270.4 million by 2025, from USD 1331.5 million in 2019.

The Circulating Tumor Cells (CTCs) Prognostic Technologies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Circulating Tumor Cells (CTCs) Prognostic Technologies market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Circulating Tumor Cells (CTCs) Prognostic Technologies market has been segmented into:
Tumor Cell Enrichment
Tumor Cell Detection

By Application, Circulating Tumor Cells (CTCs) Prognostic Technologies has been segmented into:
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market presented in the report. This section sheds light on the sales growth of different regional and country-level Circulating Tumor Cells (CTCs) Prognostic Technologies markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market.

The report offers in-depth assessment of the growth and other aspects of the Circulating Tumor Cells (CTCs) Prognostic Technologies market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share Analysis
Circulating Tumor Cells (CTCs) Prognostic Technologies competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Circulating Tumor Cells (CTCs) Prognostic Technologies sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Circulating Tumor Cells (CTCs) Prognostic Technologies sales, revenue and market share for each player covered in this report.

The major players covered in Circulating Tumor Cells (CTCs) Prognostic Technologies are:
AdnaGen
Vitatex
Epic Sciences
ACDBio
Silicon Biosystems
Celula
Rarecells
Fluxion Biosciences

【レポートの目次】

Table of Contents

1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview
1.1 Product Overview and Scope of Circulating Tumor Cells (CTCs) Prognostic Technologies
1.2 Classification of Circulating Tumor Cells (CTCs) Prognostic Technologies by Type
1.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Type in 2019
1.2.3 Tumor Cell Enrichment
1.2.4 Tumor Cell Detection
1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market by Application
1.3.1 Overview: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Ovarian Cancer
1.3.7 Pancreatic Cancer
1.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market by Regions
1.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Circulating Tumor Cells (CTCs) Prognostic Technologies (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Circulating Tumor Cells (CTCs) Prognostic Technologies Status and Prospect (2015-2025)
2 Company Profiles
2.1 AdnaGen
2.1.1 AdnaGen Details
2.1.2 AdnaGen Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AdnaGen SWOT Analysis
2.1.4 AdnaGen Product and Services
2.1.5 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.2 Vitatex
2.2.1 Vitatex Details
2.2.2 Vitatex Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Vitatex SWOT Analysis
2.2.4 Vitatex Product and Services
2.2.5 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.3 Epic Sciences
2.3.1 Epic Sciences Details
2.3.2 Epic Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Epic Sciences SWOT Analysis
2.3.4 Epic Sciences Product and Services
2.3.5 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.4 ACDBio
2.4.1 ACDBio Details
2.4.2 ACDBio Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 ACDBio SWOT Analysis
2.4.4 ACDBio Product and Services
2.4.5 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.5 Silicon Biosystems
2.5.1 Silicon Biosystems Details
2.5.2 Silicon Biosystems Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Silicon Biosystems SWOT Analysis
2.5.4 Silicon Biosystems Product and Services
2.5.5 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.6 Celula
2.6.1 Celula Details
2.6.2 Celula Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Celula SWOT Analysis
2.6.4 Celula Product and Services
2.6.5 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.7 Rarecells
2.7.1 Rarecells Details
2.7.2 Rarecells Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Rarecells SWOT Analysis
2.7.4 Rarecells Product and Services
2.7.5 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
2.8 Fluxion Biosciences
2.8.1 Fluxion Biosciences Details
2.8.2 Fluxion Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Fluxion Biosciences SWOT Analysis
2.8.4 Fluxion Biosciences Product and Services
2.8.5 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Circulating Tumor Cells (CTCs) Prognostic Technologies Players Market Share
3.2.2 Top 10 Circulating Tumor Cells (CTCs) Prognostic Technologies Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Market Share by Regions
4.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.5 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
5.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
5.2 USA Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5.3 Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
5.4 Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
6.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
6.2 Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.3 UK Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.4 France Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.5 Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
6.6 Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
7.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
7.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.4 Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.5 India Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
8 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries
8.1 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
8.2 Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
8.3 Argentina Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Circulating Tumor Cells (CTCs) Prognostic Technologies by Countries
9.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Countries (2015-2020)
9.2 Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.3 UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.4 Egypt Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
9.5 South Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue and Market Share by Type (2015-2020)
10.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Type (2019-2024)
10.3 Tumor Cell Enrichment Revenue Growth Rate (2015-2025)
10.4 Tumor Cell Detection Revenue Growth Rate (2015-2025)
11 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Segment by Application
11.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Application (2015-2020)
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Application (2019-2024)
11.3 Prostate Cancer Revenue Growth (2015-2020)
11.4 Breast Cancer Revenue Growth (2015-2020)
11.5 Colorectal Cancer Revenue Growth (2015-2020)
11.6 Lung Cancer Revenue Growth (2015-2020)
11.7 Ovarian Cancer Revenue Growth (2015-2020)
11.8 Pancreatic Cancer Revenue Growth (2015-2020)
12 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast (2021-2025)
12.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast (2021-2025)
12.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Forecast by Regions (2021-2025)
12.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.6 South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

AdnaGen、Vitatex、Epic Sciences、ACDBio、Silicon Biosystems、Celula、Rarecells、Fluxion Biosciences、

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の循環腫瘍細胞(CTC)予後技術市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。